Myriad Genetics (MYGN) Tops Q2 EPS by 7c, Beats on Revenues; 'Raises Financial Guidance for Fiscal Year 2018'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 5.63 +0.06 (1.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.57 | 52 Week High | $45.34 | |||
| Open | $5.57 | 52 Week Low | $15.92 | |||
| Day High | $5.74 | P/E | 2.42 | |||
| Day Low | $5.56 | EPS | $2.33 | |||
| Volume | 196,651 | |||||
